Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: A meta-analysis of the published literature

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
J JiangC Wu

Abstract

It remains controversial whether intensified chemotherapy with hematopoietic progenitors (ICHP) is effective for small-cell lung cancer. This meta-analysis was performed to evaluate the efficacy and safety of ICHP in patients with small-cell lung cancer. MEDLINE and EMBASE databases were searched for English-language studies published through October 12, 2008. Randomized phase II and III clinical trials comparing ICHP with control therapy. Response rates, overall survival, and toxicity were analyzed. Five assessable trials were identified including 641 patients. No significant increase in the odds ratio for response was attributable to ICHP (odds ratio, 1.29; 95% confidence interval, 0.87-1.93; p=0.206). No statistically significant increase in overall survival was found when ICHP were compared to control regimens (hazard ratio, 0.94; 95% confidence interval, 0.80-1.10; p=0.432). The toxicity of ICHP was significantly higher for hematologic toxicity, including hemoglobin nadir and platelet nadir. ICHP was not superior to control chemotherapy in terms of both objective response and overall survival, and was related to more significant hemoglobin nadir and platelet nadir.

References

Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Jun 18, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J Douglas RizzoMary M Horowitz
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea ArdizzoniUNKNOWN European Organization for Research and Treatment of Cancer-Lung Cancer Group
Oct 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V C G Tjan-HeijnenP E Postmus
Jun 16, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Roger StuppSerge Leyvraz
Jun 30, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G RostiM Marangolo
Jan 18, 2007·The Oncologist·Gino CrivellariSavina Maria Luciana Aversa
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Erika BuchholzPeter Drings
Apr 10, 2008·Journal of the National Cancer Institute·Serge LeyvrazUNKNOWN Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation

❮ Previous
Next ❯

Citations

Aug 2, 2013·Expert Opinion on Pharmacotherapy·Assunta SgambatoCesare Gridelli
Oct 23, 2012·Cancer Treatment Reviews·Antonio RossiMassimo Di Maio
Apr 28, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jing WangYonggong Yang
Feb 6, 2015·American Journal of Therapeutics·Fayez KheirAbdul Hamid Alraiyes
Apr 28, 2017·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·N Rodriguez de DiosA Rodríguez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

© 2021 Meta ULC. All rights reserved